Epidemiology of drug-resistant malaria

Lancet Infectious Diseases

Volumn 2, Issue 4, 2002, Pages 209-218

  Wongsrichanalai, Chansuda ^a   Pickard, Amy L ^b   Wernsdorfer, Walther H ^c   Meshnick, Steven R ^b  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b IL   (United States)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ATOVAQUONE; CHLOROQUINE; FANSIDAR; MEFLOQUINE; MOLECULAR MARKER; PROGUANIL; PROTEIN PFCRT; PROTEIN PFMDR1; QUININE; UNCLASSIFIED DRUG;

AFRICA; DRUG EFFICACY; DRUG SENSITIVITY; GENETIC POLYMORPHISM; GEOGRAPHIC DISTRIBUTION; MALARIA CONTROL; MALARIA FALCIPARUM; MULTIDRUG RESISTANCE; MYANMAR; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW; THAILAND;

EID: 0036242351     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(02)00239-6     Document Type: Review

References (74)

1. The ears of the hippopotamus: Manifestations, determinants, and estimates of the malaria burden
2. Resistance of human malaria I, III, and IV
3. The dynamics of drug resistance in Plasmodium falciparum
4. The epidemiology of drug-resistant malaria
5. Drug resistant malaria on the Thai-Myanmar and Thai-Cambodian borders
6. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand
7. The history of antimalarial drugs
8. From quinine to qinghaosu: Historical perspectives
9. Old and new plasmodicides
10. Chloroquine-resistant malaria
11. Antimalarial drug resistance and combination chemotherapy
12. Modern chemotherapeutic options for malaria
13. Transmission control and drug resistance in malaria: A crucial interaction
14. Epidemiology of drug resistance in malaria
15. Modelling a predictable disaster: The rise and spread of drug-resistant malaria
16. Serial studies on the evolution of drug resistance in an area of East Africa receiving intermittent chemosuppression
17. The public health impact of chloroquine resistance in Africa
18. Quinine sensitivity of isolates of Plasmodium falciparum from the coast of Kenya
19. Plasmodium falciparum: Susceptibility in vitro and in vivo to chloroquine and sulfadoxine-pyrimethamine in Ghanaian schoolchildren
20. Chemoresistance of P falciparum in urban areas of Yaounde, Cameroon: Part 1, surveillance of in vitro and in vivo resistance of Plasmodium falciparum to chloroquine from 1994 to 1999 in Yaounde, Cameroon
21. A molecular marker for chloroquine-resistant falciparum malaria
22. Genetic mapping of the chloroquine-resistance locus on Plasmodium falciparum chromosome 7
23. Mutations in the P falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance
24. Analysis of pfcrt point mutations and chloroquine susceptibility in isolates of Plasmodium falciparum
25. Analysis of the key pfcrt point mutation and in vitro and in vivo response to chloroquine in Yaounde, Cameroon
26. High-level chloroquine resistance in Sudanese isolates of Plasmodium falciparum is associated with mutations in the chloroquine resistance transporter gene pfcrt and the multidrug resistance gene pfmdr1
27. Prevalence of the K76T mutation in the putative Plasmodium falciparum chloroquine resistance transporter (pfcrt) gene and its relation to chloroquine resistance in Mozambique
28. Plasmodium falciparum malaria in Laos: Chloroquine treatment outcome and predictive value of molecular markers
29. Sequence polymorphisms in pfcrt are strongly associated with chloroquine resistance in Plasmodium falciparum
30. Analysis of the PfCRT K76T mutation in Plasmodium falciparum isolates from the Amazon region of Brazil
31. Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda
32. Polymorphism of the Pfmdr1 gene and chloroquine resistance in Plasmodium falciparum in The Gambia
33. Correlation of in vivo-resistance to chloroquine and allelic polymorphisms in Plasmodium falciparum isolates from Uganda
34. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand
35. Characterization of Plasmodiurn falciparum isolated from the Amazon region of Brazil: Evidence for quinine resistance
36. Analysis of mefloquine resistance and amplification of pfmdr1 in multidrug-resistant Plasmodium falciparum isolates from Thailand
37. Pfmdr1 Asn1042Asp and Asp1246Tyr polymorphisms, thought to be associated with chloroquine resistance, are present in chloroquine-resistant and -sensitive Brazilian field isolates of Plasmodium falciparum
38. Mutations in the pfmdr1, dhfr and dhps genes of Plasmodium falciparum are associated with in-vivo drug resistance in West Papua, Indonesia
39. Analysis of pfmdr1 and drug susceptibility in fresh isolates of Plasmodium fatciparum from subsaharan Africa
40. Molecular epidemiology of Plasmodium falciparum antifolate resistance in Vietnam: Genotyping for resistance variants of dihydropteroate synthase and dihydrofolate reductase
41. Molecular analysis of DHFR and DHPS genes in P. falciparum clinical isolates from the Haut-Ogooue region in Gabon
42. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance
43. Point mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum isolates from Venezuela
44. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase of isolates from the Amazon region of Brazil
45. Amplification of pfmdr 1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand
46. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin
47. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum
48. Plasmodium falciparum: Linkage disequilibrium between loci in chromosomes 7 and 5 and chloroquine selective pressure in Northern Nigeria
49. Resistance of Plasmodium falciparum malaria to sulphadoxine-pyrimethamine ('Fansidar') in a refugee camp in Thailand
50. Malaria reemergence in the Peruvian Amazon region
51. High level of resistance of Ptasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania
52. Sulfadoxine-pyrimethamine for the treatment of Plasmodium falciparum malaria in Gabonese children
53. Chloroquine and sulfadoxine-pyrimethamine-resistant falciparum malaria in vivo - A pilot study in rural Zambia
54. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: Genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites
55. The changing in vitro susceptibility pattern to pyrimethamine/sulfadoxine in Plasmodium falciparum field isolates from Kilifi, Kenya
56. In vitro susceptibility of Tanzanian wild isolates of Plasmodium falciparum to artemisinin, chloroquine, sulfadoxine/pyrimethamine and mefloquine
57. In vitro susceptibility of Plasmodium falciparum to chloroquine, amodiaquine, quinine, mefloquine, and sulfadoxine/pyrimethamine in Equatorial Guinea
58. Follow-up of the susceptibility of Plasmodium falciparum to antimalarials in Gabon
59. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine
60. Pyrimethamine- sulfadoxine resistance in Plasmodium falciparum: What next?
61. Patterns of Plasmodium falciparum drug resistance in nonimmune travellers to Africa
62. The rise and fall of mefloquine as an antimalarial drug in Southeast Asia
63. In vitro susceptibility of Pfalciparum isolates from Myanmar to antimalarial drugs
64. Mefloquine resistant malaria in Cameroon and correlation with resistance to quinine
65. Mechanisms of artemisinin resistance in Plasmodium yoelii
66. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: A prospective study
67. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria
68. Combination therapy for malaria in Africa: Hype or hope?
69. Antimalarial drug combination policy: A caveat
70. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania
71. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro
72. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site